First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis-Reference-Cited by-同舟云学术

First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis

Published:2021-07 Issue:7 Volume:43 Page:1253-1264.e5
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Li SiNi,Li JianHe,Peng LiuBao,Tan ChongQing,Zeng XiaoHui,Peng CiYan,Zhang Chang,Li YaMin,Wan XiaoMin

Funder

Health and Family Planning Commission of Hunan Province

National Natural Science Foundation of China

Natural Science Foundation of Hunan Province

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference39 articles.

1. Multiple myeloma: an overview of management;Bird;Palliat Care Soc Pract,2019

2. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management;Rajkumar;Am J Hematol,2020

3. Economic evaluation of adding daratumumab to a regimen of bortezomib + dexamethasone in relapsed or refractory multiple myeloma: based on the latest updated analysis of CASTOR;Zeng;Clin Ther,2020

4. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020;Kumar;J Natl Compr Canc Netw,2019

5. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic literature review of health economic models developed for multiple myeloma to support future analyses;Journal of Medical Economics;2023-01-09

2. Daratumumab + chemotherapy for newly diagnosed, transplant-ineligible multiple myeloma: survival benefits at acceptable cost;PharmacoEconomics & Outcomes News;2021-07